FATE supply chain intelligence for Fate Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Fate Therapeutics, Inc. (FATE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay … |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay … |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from FATE graph: Reciprocal relationship from BMY graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legisl… |
| BMY | Bristol-Myers Squibb Company | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | ce with the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial cond… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | Reciprocal relationship from CGEM graph: Reciprocal relationship from FATE graph: ce with the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or d… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from GDTC g… |
| IPSC | Century Therapeutics, Inc. | 72% | Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legi… |
| IPSC | Century Therapeutics, Inc. | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | Reciprocal relationship from KYTX graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay … |
| LEGN | Legend Biotech Corporation | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from FATE graph: Reciprocal relationship from REGN graph: Reciprocal relationship from FATE graph: ce with the GDPR and relevant local… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ce with the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial cond… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | Reciprocal relationship from RNAC graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay … |
| RNAC | Cartesian Therapeutics, Inc. | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from FATE graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from FATE graph: th the GDPR and relevant local le… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | th the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | 72% | Reciprocal relationship from ALLO graph: Reciprocal relationship from FATE graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from FATE graph: rt that a claim including items or … |
| ALLO | Allogene Therapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| ARTV | Artiva Biotherapeutics, Inc. | 72% | Reciprocal relationship from ARTV graph: Reciprocal relationship from FATE graph: Reciprocal relationship from ARTV graph: Reciprocal relationship from FATE graph: rt that a claim including items or … |
| BMY | Bristol-Myers Squibb Company | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitute… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| CGEM | Cullinan Therapeutics, Inc. | 72% | Reciprocal relationship from CGEM graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitut… |
| GDTC | CytoMed Therapeutics Limited | 72% | Reciprocal relationship from GDTC graph: ign or implementation of our pre-clinical studies and clinical trials; ● changes in regulatory requirements or guidance that may require us to amend or submit… |
| IPSC | Century Therapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| IPSC | Century Therapeutics, Inc. | 72% | Reciprocal relationship from IPSC graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitut… |
| KYTX | Kyverna Therapeutics, Inc. | 72% | Reciprocal relationship from KYTX graph: Reciprocal relationship from FATE graph: Reciprocal relationship from KYTX graph: Reciprocal relationship from FATE graph: rt that a claim including items or … |
| KYTX | Kyverna Therapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| LEGN | Legend Biotech Corporation | 72% | Reciprocal relationship from LEGN graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitut… |
| LEGN | Legend Biotech Corporation | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitut… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| RNAC | Cartesian Therapeutics, Inc. | 72% | Reciprocal relationship from RNAC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from RNAC graph: Reciprocal relationship from FATE graph: Reciprocal relationship from RNAC g… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from FATE graph: rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitu… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | rt that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA or federal civil monetary p… |
| CO-LTD | CO-LTD | 62% | nts to assess whether they are within the scope of ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the act… |
| REDMILE-GROUP-LLC | REDMILE-GROUP-LLC | 62% | lance sheets, with $ 3.2 million classified as current and the remaining $ 0.8 million as non-current, based on the portion expected to be payable within twelve months from the balance sheet date. 4.… |
| SRPT | Sarepta Therapeutics, Inc. | 62% | Reciprocal relationship from SRPT graph: Reciprocal relationship from FATE graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from FATE graph: Reciprocal relationship from SRPT g… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| FATE-DEBT | Debt stack $23.4M | 90% | Market cache reports total debt of $23.4M. |
| FATE-DEBT-9427 | Warrants outstanding: 230000 | 90% | xbrl warrant detail from xbrl 2017-12-31. |
| FATE-DEBT-9428 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2013-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| FATE-OWNER-REDMILE-GROUP-LLC | Redmile Group, LLC | 90% | 13F overlay lists Redmile Group, LLC as top holder; 155 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | 100.00 | 1 | ['customer'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| GDTC | CytoMed Therapeutics Limited | 100.00 | 1 | ['customer', 'supplier'] |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 1 | ['customer', 'supplier'] |
| ARTV | Artiva Biotherapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CGEM | Cullinan Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['customer', 'supplier'] |
| IMTX | Immatics N.V. | 100.00 | 2 | |
| IPSC | Century Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| RNAC | Cartesian Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| GILD | Gilead Sciences, Inc. | 100.00 | 2 | |
| ACET | Adicet Bio, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 50.00 | 2 | |
| CHKP | Check Point Software Technologies Ltd. | 50.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 50.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 |